T Cells in Type 1 Diabetes Cross-React Between Insulin and Hybrid Peptides Containing Neuropeptide Y Fragments

Diabetogenic T cell clones cross-react between native proinsulin and hybrid insulin peptides fused to neuropeptide Y and IAPP fragments, with crystal structures revealing distinct TCR recognition mechanisms.

Tran, Mai T et al.·The Journal of biological chemistry·2024·Moderate Evidencein vitro
RPEP-09404In vitroModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Moderate Evidence
Sample
N=N/A
Participants
Human islet-infiltrating T cell clones and crystallographic analysis

What This Study Found

Five of seven diabetogenic TCRs cross-reacted between proinsulin C-peptide and hybrid insulin peptides containing NPY and IAPP fragments, with structural studies revealing position-specific determinants of cross-reactivity at P2, P7, and P8.

Key Numbers

Two peptides studied: PI40-54 (proinsulin C-peptide) and HIP PI40-47-IAPP74-80 (hybrid insulin peptide); presented by HLA-DQ8.

How They Did This

T cell activation assays with SKW3 cell lines expressing diabetogenic TCRs, crystal structures of TCR-peptide-HLA-DQ8 complexes, and alanine scanning mutagenesis to identify key recognition residues.

Why This Research Matters

Understanding how diabetogenic T cells recognize and cross-react with hybrid peptides reveals fundamental mechanisms of autoimmune diabetes and could guide the development of peptide-based tolerizing therapies or vaccines.

The Bigger Picture

Hybrid insulin peptides are a relatively new concept in autoimmunity. This study shows that the immune system's confusion between normal proinsulin and these hybrid peptides involving neuropeptide Y fragments may be a key driver of type 1 diabetes — potentially offering new therapeutic targets.

What This Study Doesn't Tell Us

T cell lines from a small number of patients; SKW3 cell system may not fully represent natural T cell responses; crystal structures represent static snapshots; limited HIP variants tested; HLA-DQ8-restricted findings may not generalize to other HLA types.

Questions This Raises

  • ?Could tolerizing patients to these specific hybrid peptides prevent type 1 diabetes progression?
  • ?Do HIPs containing NPY fragments form naturally in the pancreas of pre-diabetic individuals?
  • ?How prevalent is cross-reactive T cell recognition of these HIPs across the type 1 diabetes patient population?

Trust & Context

Key Stat:
5/7 TCRs cross-reactive diabetogenic T cell clones recognized both proinsulin and hybrid insulin peptides with NPY fragments
Evidence Grade:
Strong mechanistic evidence combining functional immunology with structural biology, though limited by small numbers of patient-derived T cell clones.
Study Age:
Published in 2024, advancing understanding of hybrid insulin peptide cross-reactivity in type 1 diabetes autoimmunity.
Original Title:
A structural basis of T cell cross-reactivity to native and spliced self-antigens presented by HLA-DQ8.
Published In:
The Journal of biological chemistry, 300(9), 107612 (2024)
Database ID:
RPEP-09404

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

How do hybrid insulin peptides contribute to type 1 diabetes?

In the pancreas, fragments of different proteins (including proinsulin, neuropeptide Y, and IAPP) can fuse together creating hybrid peptides. This study shows that immune T cells trained to recognize one of these peptides can mistakenly attack cells presenting the others — potentially accelerating the autoimmune destruction of insulin-producing cells.

Could this research lead to a type 1 diabetes vaccine?

Potentially — by understanding exactly which peptide fragments the immune system confuses, researchers could design tolerance-inducing vaccines that teach the immune system to stop attacking these targets, possibly preventing or slowing type 1 diabetes.

Read More on RethinkPeptides

Cite This Study

RPEP-09404·https://rethinkpeptides.com/research/RPEP-09404

APA

Tran, Mai T; Lim, Jia Jia; Loh, Tiing Jen; Mannering, Stuart I; Rossjohn, Jamie; Reid, Hugh H. (2024). A structural basis of T cell cross-reactivity to native and spliced self-antigens presented by HLA-DQ8.. The Journal of biological chemistry, 300(9), 107612. https://doi.org/10.1016/j.jbc.2024.107612

MLA

Tran, Mai T, et al. "A structural basis of T cell cross-reactivity to native and spliced self-antigens presented by HLA-DQ8.." The Journal of biological chemistry, 2024. https://doi.org/10.1016/j.jbc.2024.107612

RethinkPeptides

RethinkPeptides Research Database. "A structural basis of T cell cross-reactivity to native and ..." RPEP-09404. Retrieved from https://rethinkpeptides.com/research/tran-2024-a-structural-basis-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.